You can buy Palboxen at the lowest price in the online pharmacy Nextgen.ooo . Palbociclib is an endocrine chemotherapeutic agent used in combination with other antineoplastic agents for the treatment of HER2-negative and HR-positive advanced or metastatic breast cancer. Palbociclib is a piperazine-pyridopyrimidine that acts in the cell cycle mechanism. It is a second-generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
 
Palbociclib was developed by Pfizer following a discovery that identified cyclin-dependent kinases as key regulators of cell growth. It was initially approved by the FDA in March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, and its indication was updated in April 2019 to include male patients based on post-marketing reports and electronic medical records demonstrating safety and clinical efficacy. Breast cancer begins as a group of cancer cells that invade and destroy nearby breast tissue. This growth can spread to other parts of the body, which is called metastasis. Depending on the location of the cancer cells, it can be divided into ductal carcinoma and lobular carcinoma.
 
However, other types of breast cancer include inflammatory breast cancer, Paget's disease of the breast, triple-negative breast cancer, non-Hodgkin's lymphoma, and soft tissue sarcoma. In men, breast cancer is usually treated as in postmenopausal women, and almost all cases are ductal carcinoma. Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that acts by binding to the ATP pocket with an IC50 in the range of 9-15 nmol/L. It is important to consider that it exhibits little or no activity against other kinases. CDK4/6 kinase, together with its coregulatory partner cyclin D, is involved in the G1-S transition. Therefore, inhibition of this step prevents cell cycle progression in cells in which this pathway is functional. This step involves the retinoblastoma protein phosphorylation pathway and the E2F family of transcription factors.